INTRODUCTION
Changing lifestyle is associated with high prevalence of stress, lack of physical exercise, high consumption of fat-enriched junk foods and high fructose/glucose containing soft drinks. All of these contributing factors may add to MetS. 1 MetS is defined as a bunch of several metabolic disorders including hypertension, insulin resistance, dyslipidemia, diabetes and cardiovascular disease. Management of dyslipidemia in early stages may lead to the progression of hepatic steatosis. 2 Obesity has become a global health problem and leads to the development of chronic diseases like CHD, dyslipidemia and type II diabetes, pancreatic β-cell dysfunction or overtiredness of pancreas is primarily related with resistance to insulinmediated peripheral glucose disposal and thus leads to hyperinsulinemia. 1, 3 Type 2 diabetes mellitus is a well-known high risk factor for atherosclerotic and CVD that confers a markedly increased risk of CHD and cardiovascular mortality when compared to non-diabetic patients. 4 Atherosclerosis is CVD characterized by the deposition of lipids in the artery wall and the infiltration of inflammatory cells, such as monocytes and lymphocytes. 4 Phenotypic changes in vascular SMC occur in diabetes and it leads to increased contractility, cellular proliferation, migration and extracellular matrix formation. 4, 5 Accelerated SMC causes to the atherosclerotic plaque development. 5 So, the clear mechanism is still poorly understood behind how diabetes accelerates atherosclerotic CVD.
Phytoestrogens are group of plant derived analogues that mimic the actions of mammalian estrogen, 17β-estradiol structurally and functionally bind to estrogen receptor and induce production of SHBG in the liver and affects sexual hormone metabolism. 6 Decline in estrogen hormone is also one of many contributing factors in the CVD. 7 HMG-CoA reductase inhibitors are well known drugs in the management and prevention of hyperlipidemia and lipid-related disorders. Statins like atorvastatin, rosuvastatin and pitavastatin are being selective inhibitors of HMG-CoA reductase which is ratelimiting enzyme of cholesterol biosynthesis; reducing LDL-C, VLDL-C and TG levels and also impart the additional effects of anti-inflammatory, antithrombotic properties to the atherosclerosis vascular disease and improve endothelial function. 8 However, the prolonged treatment of such drugs have found many adverse effects like hyperuricemia, myositis, diarrhea, gastric irritation, dry skin and liver failure. 9 Some of studies have suggested that the natural plant products like Trigonella foenum graecum, Murraya koenigii and Morus alba have an estrogen-like effect in the body due to the presence of phytoestrogens.
Therefore, it is a need to research over traditional plant extracts to overcome possible side effects of hypolipidemic synthetic drugs.
Murraya koenigii
Linn is an aromatic pubescent shrub generally known as "Kadhipatta" in India and curry leaves as common synonym. Hypolipidemic effects of this plant have been reported in several studies. The beneficial effects of Murraya koenigii leaves on HFFD induced hyperlipidemia in rats have very less reported in the recent literature. So, the present study was aimed to assess the hypolipidemic activity of Murraya koenigii leaves on the body weight, BSL and lipid profile in HFFD rat model.
MATERIAL AND METHODS

Drug and chemicals
Metformin and Atorvastatin as pure powder purchased from SigmaAldrich Ltd, India. Fructose obtained from Loba-chemie, India. Vanaspati ghee, egg yolk and coconut oil were procured from the local market. All reagents and chemicals used were of analytical grade and stored in a refrigerator at -4°C. The reagents were equilibrated at room temperature for 30 min before analysis. 
Collection and authentication of plant material
Preparation of Murraya koenigii leaves extracts
Methanolic and aqueous extracts of Murraya koenigii leaves were prepared by soxhletation method. About 50 g of shade dried leaves powder of Murraya koenigii was defatted by petroleum ether; dried it then packed in a cloth bag and placed in the thistle of Soxhlet apparatus. The Soxhlet continuous extraction process was continued for 4 days till the dark brown colour of aqueous extract turned to pale yellow while in case of methanolic extract, the appearance of dark green to colourless. Collected extracts were concentrated in the vacuum rotary evaporator at Government College of Pharmacy, Karad, Maharashtra, India and dried by evaporating in hot air oven at 45°C. Percentage yield of MEMK and AEMK were calculated with respect to the total quantity of powder used for the extraction.
Acute toxicity study of extracts AEMK and MEMK were performed in the acute toxicity test as per OECD-423 guidelines 10 for fixing the therapeutic dose. The dose of 2000 mg/kg b w of AEMK and MEMK taken as a starting dose and were orally administrated to two healthy Wistar rats. LD 50 was determined and 1/10 th of LD 50 was taken as therapeutic dose for the activity.
Experimental animals
Healthy Wistar rats of either sex weighing between 100-120 g were used in the study. 
Inclusion criteria
Healthy Wistar rats of either sex weighing 120-200 g.
Exclusion criteria
Rats of either sex which were previously treated with any drug or extract and if infected with disease.
Pilot study
Ten healthy Wistar rats of either sex were selected; their blood samples were collected by retro-orbital puncture method; BSL and lipid profile were assessed.
Experimental design
Thirty-six healthy Wistar rats of either sex were randomly divided into six groups (six animals per group) and they had free access to water and animal diet throughout the study period.
Induction of hyperlipidemia
Hyperlipidemia in rats was induced through HFFD model. Hyperlipidemia model was developed using a high fructose (10% fructose) added in drinking water bottle 11 and high fat (vanaspati ghee: coconut oil in ratio of 3:1) mixed with an egg yolk in dough of animal food diet. 12 HFFD was fed to rats of Group I to VI (Except Group III) throughout the study period of 14 weeks. Drugs or extracts in given doses were given p. o treatment. 
Gravimetric analysis
The body weight of all rats was recorded on first and final days by using digital weighing machine. Also, percent changes of body weight of all rats were calculated.
Blood collection and preparation of serum
On the last day of experimental study, all the animals were anesthetized; blood was collected by retro-orbital puncture method; centrifuged at 10000 rpm for 10 min; analyzed BSL and lipid profile. All animals were sacrificed by cervical decapitation at the end of study.
Biochemical analysis
TC, HDL-C and TG were measured by automatic analyzer using commercial diagnostic kit (ERBA diagnostics Mannheim GmBH, Germany) according to the procedure described in the manufacturer's operation manual. VLDL-C and LDL-C were estimated by using Friedewald's equation. 13 AIP was calculated. 
Statistical analysis
Data were expressed as Mean ± SEM. Data were analyzed using Graph Pad Prism 5.0 software (Graph Pad, San Diego, CA) and two-way repeated ANOVA and Tukey's test was applied for post-hoc analysis. The value of p < 0.05 was considered to be statistically significant.
RESULTS
Percentage yield
Percentage yield was found to be AEMK (14.35%) and MEMK (13.75%) with respect to the total quantity of powder used for the extraction.
Acute toxicity study of extracts
The acute toxicity study observed no mortality or any toxic reactions within 4 h and after 14 days by oral administration of AEMK and MEMK even at the highest dose (2000 mg/kg). The dose of 200 mg/kg was considered safe at 1/10 th dose of LD 50 which was in agreement with report by Lanjhiyana et al. (2011) . 15 
Pilot study of BSL and lipid profile
Body weight, BSL and lipid profile of ten rats were assessed. BSL and lipid profile were established for the normal range reference as shown in Table 1 . All values are shown which is in mostly agreement with the results of study by Ahangarpour et al. (2016) . 16 
Effect of Murraya koenigii leaves extracts on body weight
Body weight was calculated on first and final days of the experimental study period as shown in Table 2 . Extremely significant effect on body weight (p < 0.001) in Groups I, IV and V while no significant change were observed in Group II when compared to group VI. Percentage change in body weight was found highly significant change (p < 0.01) in Group I, significant change (p < 0.05) in Group V whereas no significant change were observed in Group II when compared to Group VI.
Effect of Murraya koenigii leaves extracts on glycemic profile
BSL was evaluated on first and final days of the experimental study period depicted in Table 3 . No significant difference was found in BSL among all groups.
Effect of Murraya koenigii leaves extracts on lipid profile
Lipid profile was evaluated on the final day of the experimental study period, depicted in Table 4 . Group I and II were given treatment of AEMK and MEMK respectively while Group IV and V were given treatment of standard drugs i.e., Metformin and Atorvastatin correspondingly. Group III and VI were considered as normal control and as hyperlipidemia controls respectively. Highly significant hypocholesterolemic effect (p < 0.01) was observed in Groups II, IV and V when compared to group VI. Group V revealed significant effect (p < 0.05) on TG, VLDL-C and highly significant ameliorated effect (p < 0.01) on HDL-C in comparison to group VI. Groups II and IV showed highly significant hypolipidemic effect (p < 0.01) on LDL-C ascompared to Group VI.
Effect of Murraya koenigii leaves extracts on atherogenic index of plasma
AIP was analyzed by the given formula shown in Table 5 . Groups I, IV and V showed an extremely significant result (p < 0.001) while group 27 while MEMK is in conformity with the methanolic extract of this plant in study by Vinuthan et al. (2007) . 27 They have reported the antihyperlipidemic effect of Murraya koenigii leaves in terms of lipid profile only. II exhibited significant difference (P < 0.01) in AIP when compared to group VI.
Rats
BSL (mg/dL) TC (mg/dL) TG (mg/dL) VLDL-C (mg/dL) LDL-C (mg/dL) HDL-C (mg/dL) AIP
DISCUSSION
Fructose intake may be associated with an increased risk of diabetes, hyperlipidemia and obesity through several mechanisms and also increases body weight due to the positive energy balance. Positive energy balance is associated with higher levels of non-esterified fatty acids, reduced insulin sensitivity; increased hepatic glucose production. 17 High fat fructose diet pattern has increased significantly the body weight and induced hyperlipidemia but not enhanced BSL in the present study. Our findings of the present study have shown that there was no significant change in BSL in the1 st and 14 th days of experimental study period which is in consistency with the study reported by Lozano et al. (2016) . 18 Our results of the study has indicated that HFFD model does not induce hyperglycemia in the The phytochemical constituents of Murraya koenigii have been reported for various pharmacological activities. 28 Some of them have proven as potential nutraceutical for diabetes and cardioprotective activity. An extensive range of phytochemicals such as carbazole alkaloids, essential oil, carotenoids-lutein, phenolics, terpenoids, α-tocopherol, minerals, fibers, nicotinic acid, vitamin C etc. were reported in curry leaves. 28 Based on the reports in the present study, the mechanism of antihyperlipidemic effect of Murraya koenigii could not be explained exactly. However, we suggested that higher concentration of genistein, diphenolic phytoestrogens present in Murraya koenigii might be responsible for this effect. 3 Dyslipidemia is a lipid metabolic disorder characterized by elevated levels of TC, TG, LDL-C, VLDL-C and lowered level of HDL-C 29 and considered as one of coronary risk factors in contributing to CVD. In the present study, both of AEMK and MEMK have showed hypolipidemic effects in HFFD-fed rats. HFFD pattern for the period of 14 weeks could be responsible to induce elevated levels of TC, TG and LDL-C in comparison to the normal control group. Both of AEMK and MEMK have exhibited an important role in lowering levels of TC and LDL-C in compared to group VI remarkably. Furthermore, the two possible mechanisms of preventing LDL oxidation explained in the hypothesis here that Murraya koenigii leaves increases HDL level by activating the enzyme, HDL-associated paraoxanase and protecting this enzyme from cell damage 29 and another is as redistribution of lipoproteins due to the presence of bioactive compounds like flavonoids and phenolics. 30 In our previous study, Murraya koenigii leaves has proven as potent free radical scavenger in the DPPH assay 31 so that bioactive compounds are involved in depleting TC levels through two possible mechanisms i.e. reducing fat absorption in the digestive system and increasing fat excretion into faeces. 29 Recently, the antihyperlipidemic efficacy of curry leaves on the lipid profile of menopause women has been reported in the randomized controlled pilot study by improving HDL-C and lowering TG and LDL-C. 28 However, we think this may be showed an additive effect since it is combination therapy of curry leaves with cucumber, so further extensive studies are needed to confirm this hypolipidemic activity of curry leaf as a single therapy in animal models as well as human trials. If proven in human trials, this can be used as adjuvant to the existing hypolipidemic drugs.
CONCLUSION
Results of the present study have suggested that the antihyperlipidemic activity of Murraya koenigii leaves leading to decrease serum lipid parameters mainly TC, LDL-C along with atherogenic risk is due to the presence of its bioactive compounds.
